
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$4.40
−US$1.035 · -19.04%
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
前收盤價
US$4.40
−US$1.035 · -19.04%
盤中時間採用ET。市場資料可能有所延遲。
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
日內區間
目前US$4.40
52週區間
目前US$4.40
盤中時間採用ET。市場資料可能有所延遲。
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
日內區間
目前US$4.40
52週區間
目前US$4.40
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3872.8萬 USD | 4692.6萬 USD | 4021.4萬 USD | 3183.8萬 USD | 4131.4萬 USD |
| 銷貨成本 | 1459.8萬 USD | 1700.1萬 USD | 1631萬 USD | 1360.7萬 USD | 2336.9萬 USD |
| 毛利 | 2413萬 USD | 2992.5萬 USD | 2390.4萬 USD | 1823.1萬 USD | 1794.5萬 USD |
| 研究與開發 | 64.2萬 USD | 67.6萬 USD | 63.6萬 USD | 70.3萬 USD | 188.2萬 USD |
| 銷售、一般及管理費用 | 1940.4萬 USD | 2114.1萬 USD | 1959.6萬 USD | 2009.8萬 USD | 2373.6萬 USD |
| 營業費用 | 2004.6萬 USD | 2181.7萬 USD | 2110萬 USD | 2207.1萬 USD | 2968.2萬 USD |
| 利息支出 | 16.8萬 USD | 65.9萬 USD | 100.8萬 USD | 100.8萬 USD | 104萬 USD |
| 折舊和攤銷 | 82.1萬 USD | 74.8萬 USD | 160.1萬 USD | 256萬 USD | 537.4萬 USD |
| 營業利益 | 408.4萬 USD | 810.8萬 USD | 280.4萬 USD | −384萬 USD | −1173.7萬 USD |
| 淨利 | 2457.5萬 USD | 670.2萬 USD | 80.2萬 USD | −586.5萬 USD | −1474.6萬 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年8月27日 | 1:5 | — | — |
股票分割 | 2020年1月15日 | 1:10 | — | — |
股票分割 | 2016年12月29日 | 1:10 | — | — |
已生效 2026年8月27日
1:5
已生效 2020年1月15日
1:10
已生效 2016年12月29日
1:10
AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。